Skip to content

Released Nov 9, 2023, after the close

10-Q filed Nov 9, 2023, 40 days after period end · 0001390478-23-000024

Q3 2023 · 10-Q
Revenue$0.00— vs Q3 2022no prior Q2 2023 on file
Net Income-$9.27MN/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.33N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$9,361,000N/M
Operating Cash Flowderived-$6,892,000N/M

What the release said

The release

Same quarter

MetricQ3 2023Q3 2022Q3 2021Q3 2020
Revenue$0.00$0.00$0.00$0.00
Net Income-$9.27M-$7.02M-$7.09M-$4.47M
EPS Diluted-$0.33-$0.34-$0.45-$0.53

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR